Guidant BioTherapeutics
Guidant BioTherapeutics
Insights and Research
Insights and Research
Stay up to date with the latest research, clinical progress and scientific perspectives from the Guidant BioTherapeutics team.
Stay up to date with the latest research, clinical progress and scientific perspectives from the Guidant BioTherapeutics team.
ALL
ALL
Research Updates
Research Updates
Clinical Progress
Clinical Progress
Scientific Perspectives
Scientific Perspectives
Dec 2, 2025 • 9:17 AM EST
Dec 2, 2025 • 9:17 AM EST
Research and devlopment
Research and devlopment
Read article
Read article
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Dec 2, 2025 • 9:17 AM EST
Dec 2, 2025 • 9:17 AM EST
Research and devlopment
Research and devlopment
Read article
Read article
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Dec 2, 2025 • 9:17 AM EST
Dec 2, 2025 • 9:17 AM EST
Research and devlopment
Research and devlopment
Read article
Read article
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Dec 2, 2025 • 9:17 AM EST
Dec 2, 2025 • 9:17 AM EST
Research and devlopment
Research and devlopment
Read article
Read article
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Dec 2, 2025 • 9:17 AM EST
Dec 2, 2025 • 9:17 AM EST
Research and devlopment
Research and devlopment
Read article
Read article
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Dec 2, 2025 • 9:17 AM EST
Dec 2, 2025 • 9:17 AM EST
Research and devlopment
Research and devlopment
Read article
Read article
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
LOAD MORE ARTICLES
LOAD MORE ARTICLES
Publications
Publications
View all publication
View all publication
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
Published in Frontiers in Immunology
December 2024 |
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
Published in Frontiers in Immunology
December 2024 |
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
Published in Frontiers in Immunology
December 2024 |
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
Published in Frontiers in Immunology
December 2024 |
December 2024 |
Guidant BioTherapeutics
Guidant BioTherapeutics
© 2026 Guidant BioTherapeutics, Inc. All Rights Reserved.
© 2026 Guidant BioTherapeutics, Inc. All Rights Reserved.
CONTACT
CONTACT
newsletter
newsletter
Guidant Biotherapeutics
Blogs and publications
Stay up to date with the latest research, clinical progress and scientific perspectives from the Guidant BioTherapeutics team.
ALL
Research Updates
Clinical Progress
Scientific Perspectives
Dec 2, 2025 • 9:17 AM EST
Research and devlopment
Read article
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Dec 2, 2025 • 9:17 AM EST
Research and devlopment
Read article
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
Dec 2, 2025 • 9:17 AM EST
Research and devlopment
Read article
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
LOAD MORE ARTICLES
Publications
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
December 2024 |
SON-1010 (aka GDT-001): an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Published in Frontiers in Immunology
December 2024 |
View all publication